Abstract
Hypercholesterolemia is one of the greatest risk factors of cardiovascular diseases. Despite of the wide range of available lipid lowering treatment, we are still not successful enough in reaching of LDLcholesterol targets.
At the beginning of 21st century only statins (at that time without the most effective of the them - rosuvastatin) and fenofibrate were available. With expanding the lipid lowering treatment portfolio by ezetimibe and PCSK9 inhibitors, we are able to significantly increase the percentage of patients achieving LDLcholesterol target value and thereby reduce their cardiovascular risk.
Unfortunately, although both of these medications are commonly available in the Czech Republic, their use is insufficient. Another promising treatment could be inclisiran, but there are no reimbursement conditions from health insurance in the Czech Republic available yet, on the other hand, it seems, another lipid lowering agent - bempedoic acid, will be available soon.